US IDE Sponsor of Record Explained: 21 CFR 812.18 and What Foreign Device Companies Must Know

The Rule First: 21 CFR 812.18(a) and Why It Matters

Under 21 CFR 812.18(a), a company located outside the United States cannot itself hold an Investigational Device Exemption (IDE) with FDA. The regulation states: 'A sponsor who is not a United States person shall designate a United States agent to act as sponsor or to be responsible for the investigation.' You can read the full text at the eCFR section 812.18.

In plain terms: if your company is headquartered in Germany, South Korea, Israel, Canada, or anywhere outside the United States, you need a US person or entity to stand in as the IDE sponsor before FDA. That person or entity is commonly called a US Sponsor of Record, and they carry every obligation in 21 CFR Part 812, not as a pass-through, but as the named, accountable party.

What Is an IDE Sponsor? The 21 CFR 812.3(n) Definition

FDA defines 'sponsor' at 21 CFR 812.3(n) as: 'a person who initiates, but who does not actually conduct, the investigation, i.e., the investigational plan is carried out by a person under the immediate direction of the sponsor rather than by the sponsor.' A sponsor may also be a sponsor-investigator if they both initiate and conduct the study at their own site, but for most device companies the sponsor and investigator roles are separate.

The sponsor is not simply a mailing address for FDA correspondence. The sponsor owns the IDE application, owns all correspondence with FDA and Institutional Review Boards (IRBs), and is legally accountable if sponsor obligations under Part 812 are not met.

Part 812 Subpart C Sponsor Obligations at a Glance

The table below maps the core Subpart C obligations that transfer to the US Sponsor of Record. Every one of these sections applies in full; there is no partial transfer.

• 21 CFR 812.40 (Responsibilities of Sponsors): The sponsor shall select qualified investigators, provide them with the investigational plan and report of prior investigations, ensure proper monitoring of the study, submit required reports to FDA and reviewing IRBs, and maintain required records.
• 21 CFR 812.43 (Selecting Investigators and Monitors): The sponsor must select investigators qualified by training and experience and obtain a signed investigator agreement (FDA Form 3455) from each site before shipment of devices.
• 21 CFR 812.44 (Approval of Investigators): Sponsors must obtain IRB approval at each site. If FDA has approved the IDE, the sponsor must obtain IRB approval separately before initiating the investigation at that site.
• 21 CFR 812.45 (Disposing of Device): The sponsor controls where investigational devices are shipped, how they are accounted for, and how unused devices are returned or disposed of at study close.
• 21 CFR 812.46 (Monitoring Investigations): The sponsor must monitor the investigation to ensure compliance with the investigational plan, the signed investigator agreement, and applicable FDA regulations. This includes site visits and review of records.
• 21 CFR 812.150 (Reports): The sponsor prepares and submits all IDE progress reports, deviations, supplemental applications, and final reports. Reports of unanticipated adverse device effects are due within ten working days of first receiving notice.
• 21 CFR 812.140 (Records): The sponsor maintains records of the investigational plan, device shipments, signed investigator agreements, adverse effect reports, and all correspondence with FDA and IRBs for a period of two years after the later of device approval or discontinuation of the investigation.

Significant Risk Versus Nonsignificant Risk Studies

The sponsor determination of significant risk (SR) or nonsignificant risk (NSR) is itself a sponsor obligation. For NSR studies, an abbreviated IDE pathway applies, but the sponsor of record still carries monitoring, recordkeeping, and IRB correspondence obligations under 21 CFR 812.2(b). Getting this classification wrong carries real regulatory consequences, so it is worth having a qualified regulatory professional review the determination before study initiation.

Why a Non US Company Cannot Simply Name a US Distributor

Many non US device companies assume that their US distributor or a US law firm can serve as a nominal sponsor. This misunderstands the obligation. The US Sponsor of Record must be operationally capable of fulfilling every Part 812 duty: preparing IDE submissions, communicating directly with FDA reviewers, conducting or overseeing monitoring visits, and submitting adverse event reports on time. A mailbox arrangement that lacks regulatory infrastructure exposes the entire study to a clinical hold or IDE withdrawal.

How ADB Consulting and CRO Inc. Serves as Your US Sponsor of Record

ADB Consulting and CRO Inc. (adbccro.com) serves as the named US Sponsor of Record for non US medical device companies conducting FDA IDE studies, assuming full Part 812 sponsor obligations so your team can focus on device development and clinical execution. Learn more at adbccro.com/us-sponsor.

Reviewed October 18, 2026 by ADB's regulatory team.

Frequently Asked Questions

Who must be the US Sponsor of Record for an FDA IDE study?

Under 21 CFR 812.18(a), any non US entity that initiates an IDE investigation must designate a US person or US legal entity to act as sponsor. That US sponsor carries all obligations in 21 CFR Part 812 directly to FDA. A foreign parent company, even one with a US subsidiary that lacks regulatory capacity, may still require a qualified external US Sponsor of Record to meet these obligations in practice.

What does a US Sponsor of Record engagement with ADB typically involve?

Engagements are scoped based on study complexity, number of investigational sites, device risk classification, and projected duration. ADB will assess your protocol, existing IDE documentation, and site footprint during a free discovery call and provide a transparent scope and fee proposal. Because every study differs, published pricing ranges are less useful than a direct scoping conversation.

Can the non US company remain involved in the study if ADB is the Sponsor of Record?

Yes. The non US company typically functions as the device developer and provides technical data, investigational plans, and device supply. ADB, as the US Sponsor of Record, reviews all submissions before they reach FDA, signs all FDA and IRB correspondence, and maintains the Part 812 records. The two parties operate under a written agreement that defines each party's responsibilities clearly so nothing falls through the gaps.

Ready to Assess Your IDE Sponsor of Record Needs?

If your company is preparing an FDA IDE application and is headquartered outside the United States, the first step is a structured regulatory review of your study design, risk classification, and sponsor obligations. Book a free discovery call with ADB Consulting and CRO Inc. at adbccro.com/us-sponsor and let our team assess the right path forward for your program.

If this applies to your program, our US Sponsor of Record program walks through the process in detail.